Skip to main
ANIP

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals, Inc. is positioned for growth through its expansion of the Cortrophin sales force, which has proven to be a key driver of revenue success. The company's data-driven strategies have not only enhanced its capacity to address payer-related inquiries but have also led to an increase in revenue estimates for Cortrophin, indicating potential for outperforming previous expectations. This financial flexibility and improved sales dynamics contribute positively to ANI's outlook, suggesting opportunities for revenue growth in both the rare disease and generics segments.

Bears say

ANI Pharmaceuticals Inc faces multiple challenges that contribute to a negative outlook on its stock. The company carries a significant debt load exceeding $600 million, which could burden financial flexibility and ability to invest in growth opportunities. Additionally, risks related to pricing across both branded and generic drugs, reimbursement, manufacturing, and competitive threats could further exacerbate the company's financial position and operational stability.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.